The estimated Net Worth of Capital Vii, L.P.Pomona Cap... is at least $65.9 Million dollars as of 23 June 2017. Capital Cap owns over 1,072,532 units of NovoCure Ltd stock worth over $47,243,368 and over the last 7 years Capital sold NVCR stock worth over $18,608,430.
Capital has made over 1 trades of the NovoCure Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 1,072,532 units of NVCR stock worth $18,608,430 on 23 June 2017.
The largest trade Capital's ever made was selling 1,072,532 units of NovoCure Ltd stock on 23 June 2017 worth over $18,608,430. On average, Capital trades about 1,072,532 units every 0 days since 2017. As of 23 June 2017 Capital still owns at least 2,741,925 units of NovoCure Ltd stock.
You can see the complete history of Capital Cap stock trades at the bottom of the page.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... und Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: